Parexel Baltimore - Early Phase Clinical Unit — Baltimore, Maryland

Parexel Baltimore - Early Phase Clinical Unit is a clinical research site located in Baltimore, Maryland, United States 21225.

Crixeo Health Trust Score: 60/100 (FAIR). This profile has not yet been claimed by the site owner.

Parexel Baltimore - Early Phase Clinical Unit has participated in 3 clinical trials.

Therapeutic areas: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation.

Sponsors: Bayer.

Sponsor Feasibility Report

Trust Score: 60/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Parexel Baltimore - Early Phase Clinical Unit?

Parexel Baltimore - Early Phase Clinical Unit has a Crixeo Trust Score of 60/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Parexel Baltimore - Early Phase Clinical Unit conducted?

Parexel Baltimore - Early Phase Clinical Unit has 3 clinical trials on record. Their work covers Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation.

Is Parexel Baltimore - Early Phase Clinical Unit accredited by Crixeo Health?

Parexel Baltimore - Early Phase Clinical Unit has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Parexel Baltimore - Early Phase Clinical Unit?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.